Durvalumab: tested in a combination

295 studies: another drug in the study is under test too. Page 1 of 3. Open to participants first (78), then studies with results posted, then the rest; newest registration first within each.

• A Phase II, Trial of Neoadjuvant Trastuzumab + Durvalumab + FLOT Targeted ImmunochemotherapyRecruitingNCT07911280Phase 2Report a problem
• A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-InvasiveNot yet recruitingNCT07876817Phase 4Report a problem
• Zolbetuximab, Durvalumab, and FLOT Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction AdenocarcinomaRecruitingNCT07872722Phase 2Report a problem
• Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or CholangiocarcinomaRecruitingNCT07780838Phase 2Report a problem
• DURATION-GC: FLOT Plus Durvalumab and TS-1 Plus Durvalumab for Resectable Gastric CancerNot yet recruitingNCT07757191Phase 2Report a problem
• A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.RecruitingNCT07679399Phase 2Report a problem
• IIT2025-03-YANG-LIFT-HCCRecruitingNCT07489976Phase 2Report a problem
• A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLCRecruitingNCT07459634Phase 2Report a problem
• A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous DurvalumabRecruitingNCT07391670Phase 1Report a problem
• HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICCRecruitingNCT07364305Phase 2Report a problem
• Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerRecruitingNCT07339059Phase 2Report a problem
• Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialRecruitingNCT07288034Phase 2Report a problem
• Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver CancerRecruitingNCT07174570Phase 2Report a problem
• Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein ThrombosisRecruitingNCT07122089Phase 2Report a problem
• Durvalumab as Consolidation for Patients LS-SCLCRecruitingNCT07055581Phase 2Report a problem
• Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.RecruitingNCT07027436Phase 3Report a problem
• FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular CarcinomaRecruitingNCT07012798Phase 2Report a problem
• Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCCRecruitingNCT06999707Phase 2Report a problem
• Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCCRecruitingNCT06999694Phase 2Report a problem
• Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology AgentsRecruitingNCT06963346Phase 1Report a problem
• Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular CarcinomaRecruitingNCT06911255Phase 1/2Report a problem
• Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)RecruitingNCT06859684Phase 2Report a problem
• A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinomaNot yet recruitingNCT06855225Phase 2Report a problem
• ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a MuRecruitingNCT06824363Early Phase 1Report a problem
• A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementRecruitingNCT06728410Phase 2Report a problem
• NEoadjuvant Olaparib Combination OvArian Cancer Targeted StudyNot yet recruitingNCT06650709Phase 2Report a problem
• Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder CancerRecruitingNCT06591650Phase 2Report a problem
• Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract CancerRecruitingNCT06546969Phase 1Report a problem
• Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract CarcinomaNot yet recruitingNCT06530823Phase 2Report a problem
• Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B CirrhosisRecruitingNCT06526104Phase 2Report a problem
• A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast CancerRecruitingNCT06508216Phase 1/2Report a problem
• Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.RecruitingNCT06492421Phase 2Report a problem
• Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.RecruitingNCT06492408Phase 2Report a problem
• Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via ITRecruitingNCT06483347Phase 2Report a problem
• Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via ITRecruitingNCT06482801Phase 2Report a problem
• Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular CarcinomaRecruitingNCT06470256Phase 1Report a problem
• Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)RecruitingNCT06441747Phase 2Report a problem
• PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung CancerRecruitingNCT06429696Phase 2Report a problem
• Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)Enrolling by invitationNCT06419179Phase 2Report a problem
• FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and PlatinumRecruitingNCT06393816Phase 2Report a problem
• HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCCRecruitingNCT06364007Phase 2Report a problem
• Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNomaRecruitingNCT06341764Phase 2Report a problem
• Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based TherapyRecruitingNCT06263153Phase 2Report a problem
• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)RecruitingNCT06103864Phase 3Report a problem
• Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction AdenocarcinomaRecruitingNCT06078709Phase 2Report a problem
• Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic CholangiocarcinomaRecruitingNCT06058663Phase 1Report a problem
• Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerRecruitingNCT06058377Phase 3Report a problem
• Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieRecruitingNCT06031233Phase 4Report a problem
• Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract CancerRecruitingNCT05935579Phase 2Report a problem
• Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for MesotheliomaRecruitingNCT05932199Phase 1/2Report a problem
• HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular CarcinomaRecruitingNCT05864755Phase 2Report a problem
• Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)RecruitingNCT05845450Phase 2Report a problem
• Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) PatientsRecruitingNCT05844046Phase 2Report a problem
• Immunotherapy and Radioembolisation for Metastatic Hepatocellular CarcinomaRecruitingNCT05809869Phase 2Report a problem
• TRUDI: TDXD+Durva in HER2+/Low IBCRecruitingNCT05795101Phase 2Report a problem
• Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBCRecruitingNCT05720260Phase 2Report a problem
• Y-90 With Durvalumab/Gem/Cis in Intrahepatic CholangioRecruitingNCT05655949Phase 2Report a problem
• Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and DurvalumabRecruitingNCT05568212Phase 2Report a problem
• Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With OligometastasesNot yet recruitingNCT05484583Phase 2Report a problem
• Durvalumab and Tremelimumab in Resectable HCCRecruitingNCT05440864Phase 2Report a problem
• The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control CancerRecruitingNCT05422690Phase 2Report a problem
• Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA TrialRecruitingNCT05382741Phase 2Report a problem
• Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for SarcomasRecruitingNCT05253131Phase 2Report a problem
• Triplex Checkpoint Inhibitors Therapy for Advanced Solid TumorsRecruitingNCT05187338Phase 1/2Report a problem
• Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II StudyRecruitingNCT04762030Phase 2Report a problem
• Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerRecruitingNCT04628767Phase 2/3Report a problem
• Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary TractRecruitingNCT04617756Phase 2Report a problem
• Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )RecruitingNCT04443322Not applicableReport a problem
• Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular CarcinomaRecruitingNCT04430452Phase 2Report a problem
• Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal CancerRecruitingNCT04083365Phase 2Report a problem
• Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCCRecruitingNCT03899428Phase 2Report a problem
• A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG StudiesRecruitingNCT03847649Phase 2Report a problem
• PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast CancerRecruitingNCT03740893Phase 2Report a problem
• Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal MalignanciesRecruitingNCT03539822Phase 1/2Report a problem
• Renal Adjuvant MultiPle Arm Randomised TrialRecruitingNCT03288532Phase 3Report a problem
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2Report a problem
• Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentRecruitingNCT02029001Phase 2Report a problem
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2Report a problem
• Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast CancerCompletedNCT05498155Phase 2Results postedReport a problem
• Regorafenib and Durvalumab for the Treatment of High-Risk Liver CancerActive, not recruitingNCT05194293Phase 2Results postedReport a problem
• Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)TerminatedNCT04989218Phase 1/2Results postedReport a problem
• A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung CancerTerminatedNCT04951115Phase 2Results postedReport a problem
• Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung CancerCompletedNCT04774380Phase 3Results postedReport a problem
• Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic AgentsActive, not recruitingNCT04739800Phase 2Results postedReport a problem
• Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT04712903Phase 3Results postedReport a problem
• Trying to Find the Correct Length of Treatment With Immune Checkpoint TherapyActive, not recruitingNCT04637594Phase 3Results postedReport a problem
• Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine TumorsTerminatedNCT04538378Phase 2Results postedReport a problem
• Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung CancerTerminatedNCT04348292Phase 1Results postedReport a problem
• Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen LoadTerminatedNCT04336943Phase 2Results postedReport a problem
• Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial CarcinomaTerminatedNCT04322643Phase 2Results postedReport a problem
• Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial CancerActive, not recruitingNCT04269200Phase 3Results postedReport a problem
• Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLCTerminatedNCT04163432Phase 2Results postedReport a problem
• Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung CancerTerminatedNCT03871153Phase 2Results postedReport a problem
• Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLCCompletedNCT03822351Phase 2Results postedReport a problem
• A Study of Olaparib and Durvalumab in Prostate CancerTerminatedNCT03810105Phase 2Results postedReport a problem
• AMTEC IIT: Phase 2 Multiarm Study in TNBCTerminatedNCT03801369Phase 2Results postedReport a problem
• Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer PatientsActive, not recruitingNCT03737643Phase 3Results postedReport a problem
• Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation TherapyActive, not recruitingNCT03703297Phase 3Results postedReport a problem
• Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT03691714Phase 2Results postedReport a problem
• Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneActive, not recruitingNCT03660826Phase 2Results postedReport a problem

← Durvalumab